acut
respiratori
distress
syndrom
ard
first
describ
adult
present
tachypnea
hypoxemia
decreas
pulmonari
complianc
sinc
understand
diagnosi
manag
ard
advanc
greatli
research
perform
adult
two
decad
pediatr
healthcar
provid
reli
heavili
adultderiv
diagnost
criteria
recent
year
pediatr
acut
lung
injuri
consensu
confer
palicc
provid
agespecif
diagnost
manag
guidelin
pediatr
ard
new
pediatricspecif
recommend
futur
research
pediatr
ard
look
promis
new
area
investig
identifi
one
area
interest
warrant
explor
role
viral
infect
develop
progress
pediatr
ard
inform
avail
specif
pediatr
much
understand
continu
deriv
adult
data
review
outlin
known
ard
attribut
viral
infect
specif
respiratori
syncyti
viru
rsv
influenza
viru
well
viralspecif
treatment
option
accur
incid
outcom
report
pediatr
ard
limit
chang
definit
ard
studi
use
american
european
consensu
confer
aecc
definit
outlin
epidemiolog
outcom
acut
lung
injuri
ali
ard
separ
entiti
howev
berlin
definit
palicc
recommend
longer
identifi
ali
separ
entiti
instead
categor
ard
mild
moder
sever
sinc
guidelin
recent
studi
conduct
determin
incid
ard
util
new
criteria
addit
manag
ard
also
chang
year
improv
outcom
demonstr
lungprotect
mechan
ventil
strategi
pediatr
studi
conduct
use
aecc
definit
defin
incid
rang
per
children
caus
aliard
predomin
etiolog
report
secondari
pneumonia
without
system
infect
recent
studi
use
berlin
definit
barreira
et
al
report
ard
account
picu
admiss
associ
high
mortal
rate
overal
incid
respiratori
viru
infect
particular
rsv
influenza
viru
lead
lower
respiratori
tract
diseas
wide
studi
frequenc
progress
pediatr
ard
yet
clearli
determin
respiratori
syncyti
viru
infect
recogn
import
caus
lower
lung
diseas
earlier
studi
dahlem
et
al
report
ard
case
due
rsvrelat
infect
specif
mortal
group
report
recent
studi
lopezfernandez
et
al
patient
admit
picu
ard
test
posit
rsv
report
mortal
studi
netherland
schene
et
al
analyz
patient
mechan
ventil
rsv
patient
progress
ard
ard
found
bacteri
coinfect
mortal
rate
use
measur
outcom
therefor
report
sinc
begin
influenza
viru
pandem
influenzarel
respiratori
failur
becom
notabl
caus
ard
pandem
postpandem
era
clear
children
particularli
vulner
diseas
even
previous
healthi
alon
case
report
estim
case
occur
patient
less
year
age
previou
year
influenzarel
pediatr
death
averag
annual
increas
pandem
postpandem
studi
suggest
decreas
influenza
viru
diseas
sever
burden
continu
signific
caus
sever
ill
pediatr
ard
retrospect
analysi
adult
patient
within
german
ard
network
investig
report
ard
patient
influenza
viru
posit
anoth
pediatr
studi
india
kinikar
et
al
report
patient
hospit
confirm
influenza
viru
develop
ard
studi
children
die
found
histolog
pulmonari
find
reflect
ard
autopsi
argentina
faria
et
al
studi
patient
admit
respiratori
failur
due
influenza
viru
found
met
criteria
pediatr
ard
die
within
day
picu
admiss
second
less
common
novel
influenza
viru
avian
influenza
viru
first
identifi
remain
common
caus
sever
respiratori
diseas
kawachi
et
al
review
pediatr
patient
ard
period
vietnam
found
patient
confirm
infect
highli
pathogen
influenza
viru
describ
rapid
progress
diseas
ard
nine
result
death
investig
led
improv
understand
transmiss
predominantli
direct
aviantohuman
transmiss
signific
risk
handl
sick
dead
poultri
type
pneumocyt
macrophag
primari
lung
target
togeth
studi
demonstr
rsv
influenza
viru
infect
play
role
develop
pediatr
ard
howev
better
understand
diseas
burden
futur
studi
seek
clearli
identifi
rate
occurr
primari
viralinduc
ard
well
incid
secondari
viralinduc
lung
injuri
furthermor
patient
coinfect
bacteri
pathogen
may
hard
determin
whether
viru
bacteria
play
incit
role
develop
progress
pediatr
ard
taken
togeth
overal
mortal
attribut
either
rsv
influenza
rel
similar
thu
like
syndrom
ard
associ
patholog
respons
outcom
rsv
influenza
viru
commonli
report
virus
lead
pediatr
ard
viral
pathogen
worth
mention
typic
viral
infect
lead
respiratori
failur
icu
separ
commun
acquir
nosocomi
commun
acquir
viral
infect
includ
season
pandem
pathogen
season
virus
commonli
includ
rsv
nonpandem
influenza
rhinovirus
parainfluenza
adenoviru
coronavirus
human
metapneumoviru
hmpv
season
virus
remain
frequent
caus
childhood
commun
acquir
pneumonia
common
etiolog
pediatr
ard
primari
pneumonia
without
system
infect
assum
viral
infect
may
play
import
role
develop
pediatr
ard
howev
determin
accur
estim
diseas
burden
viralinduc
pediatr
ard
difficult
mani
simpl
viral
infect
progress
coinfect
second
viru
bacteri
pathogen
detail
develop
multiplex
pcr
diagnost
platform
identifi
multipl
viral
agent
insight
coinfect
develop
singlecent
adult
studi
report
seven
patient
develop
ard
adenoviru
four
die
hung
lin
describ
case
male
adenovir
ard
requir
extracorpor
membran
oxygen
ecmo
hasvold
et
al
studi
adult
patient
hospit
hmpv
discov
progress
ard
patient
outbreak
enteroviru
unit
state
led
symptom
respiratori
failur
similar
influenza
viru
although
less
sever
season
virus
typic
caus
sever
infect
immunocompromis
patient
case
sever
diseas
immunocompet
patient
becom
increasingli
report
intern
level
commun
acquir
novel
pathogen
recogn
signific
caus
ard
last
year
world
health
organ
develop
panel
expert
priorit
emerg
pathogen
like
caus
sever
outbreak
near
futur
littl
prevent
cur
treatment
avail
list
includ
two
novel
coronavirus
sever
acut
respiratori
syndrom
sar
cov
merscov
wide
recogn
noteworthi
caus
ard
sarscov
led
develop
sar
china
affect
patient
age
sar
led
signific
mortal
worldwid
within
month
larg
number
infect
patient
develop
sever
complic
develop
ard
howev
report
sar
case
ceas
sinc
spread
infect
subsid
recent
second
novel
coronaviru
merscov
led
middl
east
respiratori
syndrom
clinic
symptom
rang
mild
upper
respiratori
symptom
sever
pneumonia
ard
septic
shock
multiorgan
failur
carri
estim
mortal
viru
continu
substanti
etiolog
ard
high
mortal
definit
prevent
treatment
support
care
identifi
unpredict
natur
epidem
pandem
novel
virus
illustr
need
improv
understand
viral
progress
ard
order
advanc
manag
reduc
mortal
asid
commun
acquir
viral
infect
nosocomi
infect
import
caus
respiratori
ill
lead
ard
adult
children
mechan
ventil
adult
reactiv
latent
herp
simplex
viru
hsv
oropharynx
potenti
lead
lower
respiratori
tract
infect
ard
howev
pathogen
reactiv
hsv
lower
respiratori
tract
infect
may
straightforward
remain
unclear
whether
hsv
contribut
worsen
ill
whether
reactiv
occur
due
underli
critic
ill
schuller
et
al
found
higher
level
clinic
sever
mortal
critic
ill
immunocompet
adult
infect
compar
immunocompromis
patient
true
extent
hsv
reactiv
critic
ill
children
lead
respiratori
ill
yet
studi
hennu
et
al
describ
two
previous
healthi
children
present
respiratori
failur
due
human
herp
viru
later
workup
reveal
immunodefici
patient
separ
pediatr
case
report
child
hsv
ard
result
need
extracorpor
support
case
illustr
rare
possibl
sever
infect
progress
ard
final
mani
season
pandem
virus
potenti
nosocomi
infecti
risk
secondari
either
healthcar
provid
airventil
transmiss
studi
two
influenza
season
germani
huzli
et
al
report
rate
nosocomi
transmiss
specif
guidelin
avail
help
prevent
transmiss
infecti
pathogen
isol
precaut
howev
dhar
et
al
found
increas
number
patient
place
contact
isol
led
decreas
complianc
isol
precaut
decreas
nosocomi
transmiss
within
care
area
critic
ill
patient
import
area
improv
palicc
recent
provid
guidelin
diagnos
pediatr
ard
new
guidelin
defin
import
diagnost
criteria
includ
age
time
origin
edema
imag
oxygen
patient
perinat
lung
diseas
exclud
pard
criteria
must
met
within
day
clinic
insult
caus
respiratori
failur
must
explain
heart
failur
fluid
overload
must
evidenc
new
pulmonari
infiltr
chest
radiograph
consist
parenchym
diseas
final
use
oxygen
index
prefer
pf
ratio
determin
sever
pard
mechan
ventil
patient
pf
ratio
sf
ratio
may
use
patient
requir
noninvas
ventil
clinic
guidelin
use
diagnosi
viralinduc
pediatr
ard
current
sever
differ
type
laboratori
test
commerci
avail
diagnosi
clinic
laboratori
util
antigen
detect
test
consist
multipl
step
accur
identifi
singl
viru
without
cell
cultur
worth
note
past
year
develop
refin
realtim
revers
transcriptas
polymeras
chain
reaction
rtpcr
enhanc
clinician
abil
diagnos
array
virus
rapidli
accur
multiplex
rtpcr
test
analyz
singl
sampl
multipl
viral
agent
subtyp
simultan
produc
sensit
specif
result
short
period
time
even
influenza
viru
pandem
center
diseas
control
prevent
cdc
quickli
modifi
standard
pcr
assay
detect
new
viru
challeng
routin
rtpcr
test
patient
present
viral
symptom
prohibit
cost
need
special
equip
rel
longer
time
sampl
avail
result
furthermor
pcr
detect
viral
gene
use
surrog
measur
whole
virion
instanc
viral
gene
detect
may
actual
reflect
nonrepl
noninfecti
virion
newer
rapid
pointofcar
pcr
current
develop
implic
clinic
decis
make
remain
uncertain
addit
rapid
antigen
detect
test
radt
also
avail
commerci
detect
rsv
influenza
viru
infect
outpati
emerg
depart
set
howev
recent
studi
moesker
et
al
radt
found
rel
low
sensit
compar
rtpcr
test
limit
use
clinic
decis
make
nonetheless
radt
mayb
valuabl
tool
especi
outbreak
pointofcar
test
easi
use
rapid
turnaround
time
sinc
clinic
symptom
differ
viral
respiratori
infect
often
limit
current
test
method
critic
clinician
obtain
microbiolog
data
earli
especi
risk
popul
also
larg
variabl
diseas
sever
children
infect
rsv
influenza
viru
rsv
infect
develop
lower
respiratori
track
diseas
prematur
infant
without
chronic
neonat
lung
diseas
associ
significantli
higher
risk
hospit
intens
care
unit
admiss
need
mechan
ventil
death
studi
children
lower
respiratori
infect
due
rsv
rodriguez
et
al
report
age
less
month
histori
prematur
chronic
respiratori
diseas
congenit
heart
diseas
coinfect
adenoviru
signific
predictor
increas
diseas
sever
similar
predictor
exist
children
infect
influenza
viru
includ
age
less
year
histori
chronic
lung
diseas
congenit
heart
diseas
immun
compromis
tabl
therefor
prudent
clinician
conduct
laboratori
evalu
earli
ill
viral
infect
atrisk
popul
present
respiratori
failur
ard
contrast
clinic
predictor
diseas
sever
contribut
viral
factor
diseas
burden
remain
unclear
rsv
infect
although
earlier
studi
suggest
correl
viral
load
diseas
sever
newer
find
suggest
otherwis
studi
devincenzo
et
al
houben
et
al
report
direct
correl
viral
load
diseas
sever
infant
primari
rsv
infect
el
saleebi
et
al
also
report
viral
load
independ
associ
increas
risk
patient
rsv
requir
prolong
hospit
intens
care
develop
respiratori
failur
relev
viral
load
influenza
viru
infect
unclear
laun
et
al
found
children
day
symptom
higher
influenza
viral
load
diagnosi
correl
increas
risk
requir
mechan
ventil
similarli
other
found
patient
system
symptom
pneumonia
higher
viral
load
compar
uncompl
upper
respiratori
tract
infect
alon
would
expect
children
higher
influenza
viral
load
compar
adult
less
exposur
influenza
antigen
howev
find
correl
occurr
diseas
complic
rsv
influenza
viru
result
broad
spectrum
diseas
rang
mild
upper
respiratori
symptom
fulmin
respiratori
failur
ard
high
degre
variabl
may
due
pathogen
viral
pathogen
host
immun
respons
combin
human
rsv
consist
subgroup
b
primarili
infect
human
rsv
genom
encod
differ
protein
involv
transmiss
infect
evas
host
respons
replic
infect
typic
restrict
respiratori
epitheli
cell
includ
type
type
ii
alveolar
pneumocyt
trachea
level
bronchiol
infect
lead
epitheli
interstiti
inflamm
progress
inflammatori
infiltr
epitheli
slough
infect
viral
replic
rsv
caus
epitheli
cell
fuse
form
syncytium
viru
spread
cell
cell
infect
epitheli
cell
destroy
releas
inflammatori
cytokin
chemokin
ultim
attract
addit
inflammatori
cell
degrad
capillari
integr
disrupt
barrier
result
leakag
plasma
protein
interstiti
tissu
within
alveoli
final
interf
surfact
function
understand
pathophysiolog
process
rsv
surpris
progress
ard
potenti
end
point
asid
viral
pathogen
host
immunemedi
factor
also
contribut
diseas
sever
rapidli
progress
area
research
understand
role
biomark
diagnosi
prognosi
ard
also
potenti
therapeut
option
alter
biomark
inflammatori
protein
matrix
metalloproteinas
mmp
famili
shown
elev
pediatr
ali
specif
increas
product
rsv
infect
block
vitro
vivo
result
decreas
viral
load
addit
activ
sever
chemokin
interleukin
subtyp
well
tumor
necrosi
factor
shown
posit
correl
sever
ill
children
rsv
studi
fernandez
et
al
discov
higher
level
solubl
posit
correl
diseas
sever
durat
supplement
oxygen
infant
acut
rsv
infect
separ
studi
confirm
associ
increas
level
nasopharyng
secret
pathogen
correl
yet
determin
antigen
variabl
exist
influenza
viru
result
immunemedi
respons
like
influenza
b
c
influenza
made
structur
protein
two
group
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
glycoprotein
respons
attach
entri
cell
viral
spread
throughout
respiratori
tract
capabl
larg
degre
variabl
waterfowl
serv
largest
natur
reservoir
influenza
subtyp
aviantohuman
leap
occur
direct
transmiss
altern
pig
although
transmiss
pig
human
rare
event
occur
pandem
small
outbreak
new
jersey
recent
pandem
influenza
start
influenza
viru
primarili
target
alveolar
epitheli
cell
serv
firstlin
defens
respiratori
infect
histolog
evalu
fatal
case
influenza
viru
infect
reveal
diffus
alveolar
damag
inflamm
fibrosi
edema
disrupt
surfact
product
detect
viral
antigen
throughout
lung
parenchyma
like
rsv
pathogen
process
rapidli
progress
refractori
hypoxemia
ard
addit
viral
pathogen
diseas
sever
influenza
viru
infect
also
close
associ
host
respons
healthi
patient
comorbid
influenza
viru
lead
exagger
inflammatori
respons
dysregul
local
system
chemokin
cytokin
product
studi
specif
pediatr
popul
takano
et
al
found
posit
correl
diseas
sever
elev
level
serum
interferon
gamma
sever
interleukin
type
monocyt
chemoattract
studi
suggest
elev
may
adequ
immun
respons
infect
explor
inflammatori
respons
influenza
viru
infect
like
yield
develop
potenti
intervent
prevent
diseas
progress
ard
treatment
ard
significantli
evolv
past
sever
decad
perhap
greatest
improv
manag
develop
studi
involv
lungprotect
ventil
intervent
inhal
nitric
oxid
fluid
manag
use
steroid
prone
posit
investig
valid
howev
specif
treatment
rsv
infect
remain
lack
despit
substanti
short
longterm
morbid
mortal
associ
rsv
diseas
children
current
manag
rsv
infect
consist
support
care
form
oxygen
supplement
adequ
hydrat
mechan
ventil
develop
respiratori
failur
multipl
therapeut
strategi
explor
limit
success
vital
need
remain
effect
diseas
treatment
intervent
either
viru
separ
primari
prevent
infect
typic
vaccin
reduct
infecti
burden
transmiss
alreadi
taken
place
primari
prevent
vaccin
continu
major
area
research
potenti
advanc
rsv
influenza
viru
date
rsv
vaccin
proven
efficaci
signific
research
devot
vaccin
develop
major
obstacl
specif
rsv
young
age
infect
lack
persist
immun
poorli
valid
anim
model
make
difficult
find
effect
safe
solut
one
current
prospect
liveattenu
intranas
vaccin
provid
protect
rsv
parainfluenza
although
safe
children
age
yet
show
benefici
immunogen
respons
infant
recent
advanc
continu
focu
liveattenu
vaccin
well
chimer
live
vector
vari
antibodi
respons
children
vaccin
develop
continu
prophylact
use
polyclon
rsv
intraven
immunoglobulin
respigam
human
antif
monoclon
antibodi
palivizumab
motavizumab
yet
licens
use
highrisk
infant
shown
reduc
risk
rsvassoci
acut
lower
respiratori
tract
infect
diseas
sever
palivizumab
human
monoclon
antibodi
target
block
viral
infect
cell
fuse
adjac
cell
palivizumab
shown
effect
highrisk
popul
specif
prematur
infant
chronic
lung
diseas
congenit
heart
diseas
use
palivizumab
treatment
rsv
infect
mechan
ventil
pediatr
patient
shown
effect
furthermor
studi
also
shown
palivizumab
prophylaxi
patient
limit
effect
total
diseas
burden
rsv
infect
includ
overal
rsvrelat
hospit
admiss
resourc
util
although
approv
use
unit
state
motavizumab
secondgener
deriv
palivizumab
decreas
viral
load
compar
placebo
howev
recent
studi
hospit
rsv
infect
infant
treat
motavizumab
placebo
antivir
effect
demonstr
furthermor
therapi
produc
temporari
passiv
immun
influenza
viru
novel
strain
leav
children
young
adult
littl
preexist
antibodi
without
adequ
protect
season
influenza
vaccin
alon
new
influenza
viru
vaccin
rapidli
develop
subsequ
shown
safe
effect
provid
adequ
immunolog
respons
one
postpandem
studi
show
correl
higher
rate
influenza
viru
infect
compar
influenza
type
along
increas
icu
admiss
countri
limit
number
popul
receiv
influenza
viru
vaccin
addit
gener
support
care
second
goal
therapi
viral
infect
focus
reduc
infecti
burden
theoret
subsequ
viral
sequela
current
inhal
ribavirin
approv
antivir
treatment
rsv
infect
children
use
associ
potenti
teratogen
efficaci
remain
uncertain
ribavirin
directli
indirectli
inhibit
replic
dna
rna
virus
includ
rsv
studi
infant
found
decreas
mortal
respiratori
deterior
decreas
day
hospit
day
mechan
ventil
ventil
infant
luo
et
al
report
adult
case
sever
rsv
infect
progress
ard
success
treat
inhal
ribavirin
overal
effect
treatment
viral
pediatr
ard
yet
determin
addit
use
rsv
ribavirin
also
use
treatment
sever
influenza
viru
infect
ribavirin
given
oral
typic
aerosol
use
respiratori
viral
infect
howev
safeti
consider
regard
potenti
teratogen
exposur
healthcar
worker
administr
limit
use
american
academi
pediatr
recommend
routin
use
ribavirin
treat
rsv
infect
reserv
use
patient
potenti
lifethreaten
diseas
sever
small
molecul
inhibitor
interfer
rsv
f
protein
identifi
includ
recent
evalu
challeng
safeti
studi
healthi
adult
studi
devincenzo
et
al
treatment
result
decreas
viral
burden
sever
clinic
diseas
use
small
molecul
inhibitor
context
pediatr
subject
develop
ard
remain
untest
point
neuraminidas
inhibitor
prevent
releas
influenza
virion
includ
oral
oseltamivir
inhal
zanamivir
laninamivir
parenter
peramivir
remain
firstlin
intervent
influenza
oseltamivir
peramivir
zanamivir
avail
unit
state
perhap
wide
use
oseltamivir
result
signific
decreas
durat
symptom
well
sever
ill
earli
treatment
h
symptom
use
oseltamivir
sever
case
influenza
becom
standard
practic
although
studi
shown
increas
resist
randolph
et
al
conduct
retrospect
studi
children
admit
picu
confirm
influenza
infect
overal
requir
mechan
ventil
rate
progress
ard
report
although
treat
oseltamivir
associ
improv
mortal
faria
et
al
found
reduc
mortal
patient
pard
influenza
oseltamivir
administ
within
first
h
studi
need
look
effect
antivir
medic
treatment
viralinduc
ard
recent
year
investig
also
focus
potenti
benefit
immun
modul
enhanc
research
surround
viral
pathogen
host
immun
respons
potenti
target
intervent
hope
identifi
asid
viralspecif
therapi
ecmo
util
rescu
therapi
sever
respiratori
failur
pediatr
year
surviv
overal
use
ecmo
treatment
ard
increas
improv
mortal
recent
palicc
recommend
conclud
ecmo
consid
treatment
pard
lungprotect
strategi
fail
caus
respiratori
failur
thought
revers
child
may
suitabl
lung
transplant
use
ecmo
pediatr
respiratori
failur
due
rsv
well
report
retrospect
review
children
requir
mechan
ventil
rsv
bronchiol
flamant
et
al
report
use
ecmo
patient
studi
median
durat
ecmo
day
surviv
rate
hand
use
ecmo
pard
due
influenza
viru
spars
report
understand
stem
adult
studi
studi
australia
new
zealand
influenza
pandem
adult
patient
influenzainduc
ard
treat
ecmo
median
durat
ecmo
day
report
submit
patient
surviv
icu
discharg
death
patient
remain
icu
remain
ecmo
studi
unit
kingdom
pandem
noah
et
al
discov
decreas
mortal
patient
ard
due
influenza
refer
transfer
ecmo
center
compar
match
nonecmoref
patient
studi
patient
receiv
ecmo
mortal
rate
expand
use
ecmo
within
pediatr
popul
influenza
viru
induc
ard
yet
investig
howev
use
ecmo
refractori
case
rsv
influenza
viru
induc
ard
consid
applic
clear
viral
infect
import
caus
pediatr
ard
exact
diseas
burden
remain
unknown
definit
diagnost
criteria
clinician
wide
array
research
possibl
regard
pediatr
ard
retrospect
prospect
studi
expand
understand
viralinduc
pediatr
ard
great
benefit
understand
epidemiolog
viralspecif
treatment
option
avail
addit
improv
comprehens
viral
transmiss
pathogen
host
respons
particularli
import
time
pandem
either
known
novel
virus
final
continu
effort
prevent
treatment
viral
infect
like
greatest
advantag
decreas
viral
progress
pediatr
ard
sn
rw
mk
contribut
concept
write
final
edit
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
